RE:300 million versus 700 million shares out.Maxi: Your weekend homework is to study the concept of market cap and differentiate it from sharecount. Extra credit for telling us the net worth of IBRX founder and main backer. Then, wrap it all up with your perspective on you'll personally strive to be a data-driven investor in 2025 that values all input, positive and negative. Q1 2025 is almost here. Be thinking of what you might say IF the milestones are again pushed.
Maxcitrac wrote: I would like the complainers on this board(DumDum,NotaPoop,Mikee, Infinity....)To find a single small cap company that went from nothing to FDA BTD approval without multiple delays, and with only 300 million shares out.
EX, IBRX, ImmunityBio N803+BCG did get BTD approval for a bladder cancer treatment with much inferior data compared to Theralase Ruvidar, and did it with 700 million shares out. And ImmunityBio did experience multiple delays, just like Theralase.
700 million shares out, double Theralase shares out count,Theralase has over 300 million shares out.